SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Mauryce Caesar/Shutterstock
Biopharmas Booming on the Nasdaq Today
The Nasdaq has been a hopping place this year, with new biotechs adding their symbol to the ticker every week and others flooding the market with more stock.
December 16, 2020
 · 
2 min read
 · 
Kate Goodwin
Business
From Blindness to Parkinson’s, Three Biotechs Join the Race for Better Treatments
Launching with hearty Series A rounds, these new companies are ready to run.
December 16, 2020
 · 
4 min read
 · 
Kate Goodwin
Business
Biopharma Money on the Move: December 9-15
A roundup of life sciences companies raking in the cash.
December 16, 2020
 · 
4 min read
 · 
Kate Goodwin
BioCapital
Ready, Set, Vaccinate! First COVID-19 Vaccines Administered Today in U.S.
145 hospitals and clinics received their first batch of Pfizer-BioNTech’s coronavirus vaccine today.
December 14, 2020
 · 
3 min read
 · 
Kate Goodwin
Deals
IPO Frenzy Continues as 4 More Go Public
Another four companies join the Nasdaq, bringing the life science IPO count to over 70 this year.
December 11, 2020
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Michael Vi/Getty Images
Deals
Bolstering Cancer Platform, Boehringer Acquires NBE for $1.4B USD
Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.
December 10, 2020
 · 
2 min read
 · 
Kate Goodwin
Biotech Beach
Biopharma Money on the Move: December 2 - 8
December is bringing frost in the North and plenty of cold, hard cash for these life sciences companies.
December 8, 2020
 · 
6 min read
 · 
Kate Goodwin
AbCellera Chief Executive Officer Carl Hansen
Deals
COVID-19 Antibody Discovery Company Preps for Massive $391 Million IPO
With support from Peter Thiel, Eli Lilly partner AbCellera looks to join the NASDAQ with the biggest Canadian biotech debut on record.
December 7, 2020
 · 
2 min read
 · 
Kate Goodwin
Chris Allan/Shutterstock
Business
Biden Taps California Attorney General Becerra to Lead HHS
Experts anticipated his nomination as Biden’s Attorney General instead.
December 7, 2020
 · 
2 min read
 · 
Kate Goodwin
Michel Passet / Shutterstock
Drug Development
As Death Toll Climbs, WHO Finds No Benefit with 4 Top COVID-19 Treatments
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
December 4, 2020
 · 
2 min read
 · 
Kate Goodwin
Sliverback CEO Laura Shawver, Ph.D./Courtesy Silve
BioForest
Biotech Boom Continues – Silverback Ups IPO Raise to $195 Million
Upping the numbers two times, Silverback now readies a 10 million share offering.
December 3, 2020
 · 
2 min read
 · 
Kate Goodwin
JHVEPhoto/GettyImages
FDA
FDA Works to Get New Drugs to Patients Faster with Multiple Approvals This Week
The FDA uses special designations to get new, breakthrough treatments to patients in the greatest need.
December 1, 2020
 · 
3 min read
 · 
Kate Goodwin
Business
Biopharma Money on the Move: November 25 – December 1
A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.
December 1, 2020
 · 
4 min read
 · 
Kate Goodwin
Job Trends
Growing Opportunities – The Latest Job Expansions in the Life Sciences Industry
Amidst a global pandemic, the life sciences industry is booming! BioSpace rounds up facility expansions and employment opportunities across the states and beyond.
December 1, 2020
 · 
5 min read
 · 
Kate Goodwin
Business
Potential for an Alzheimer’s Disease Treatment Appears to Be Closer Than Ever
Over a decade of research and billions of dollars have been poured into Alzheimer’s disease treatment. Experts are hopeful we could finally find a cure.
November 30, 2020
 · 
7 min read
 · 
Kate Goodwin
Load More